Tilray Brands finds itself at a critical juncture, demonstrating operational growth while simultaneously grappling with severe financial pressures. The cannabis producer’s latest quarterly results paint a picture of a company balancing ambitious expansion against a backdrop of significant accounting charges.
Financial Performance: A Mixed Picture
For its fourth fiscal quarter of 2025, Tilray reported revenue of $224.5 million. However, this was overshadowed by a substantial net loss of approximately $1.27 billion. This dramatic shortfall was primarily driven by a non-cash impairment charge of roughly $1.4 billion related to goodwill and intangible assets.
Despite these massive losses, the company’s adjusted earnings per share (EPS) of $0.02 surpassed analyst expectations. Looking at the full fiscal year 2025, Tilray recorded a net loss of $2.181 billion against revenue of $821.3 million.
The quarterly net margin came in at approximately -565%, calculated from the net loss of about $1.2679 billion and net revenue of $224.5 million.
Strategic Advances and Market Position
The company achieved a significant regulatory milestone by regaining compliance with Nasdaq listing requirements. Between August 13 and August 26, 2025, Tilray’s stock maintained a closing price above the mandatory $1.00 threshold for ten consecutive trading sessions, effectively resolving its listing concerns.
Should investors sell immediately? Or is it worth buying Tilray?
Concurrently, Tilray is strengthening its position in the European medical cannabis market. The company introduced three new EU-GMP certified cannabis varieties in Germany, Europe’s largest market, aiming to enhance product accessibility for both patients and pharmacies.
Key developments include:
* Regulatory compliance: Successful restoration of Nasdaq minimum price requirements
* European expansion: Three new medical cannabis products launched to bolster market presence in Germany
* Analyst upgrade: Jefferies Financial Group raised its price target from $1.50 to $2.00 while maintaining a “Buy” rating
* Insider confidence: CEO Irwin D. Simon acquired 165,000 shares on July 30, 2025
Market Sentiment and Leadership Confidence
Jefferies justified its increased $2.00 price target by citing potential benefits from possible cannabis reclassification in the United States. Analyst opinions remain divided, with two recommending “Buy,” four suggesting “Hold,” and an average price target of $1.94.
Demonstrating faith in the company’s direction, CEO Irwin D. Simon purchased 165,000 shares at an average price of $0.61 on July 30, 2025. This transaction increased his holdings by 4.37%.
Future Outlook in Volatile Markets
Potential federal cannabis reform in the United States continues to generate optimism across the industry. For fiscal year 2026, Tilray has provided guidance forecasting adjusted EBITDA between $62 million and $72 million. Company leadership emphasizes growth opportunities in European and other emerging international markets as key drivers for future performance.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from August 29 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 29.
Tilray: Buy or sell? Read more here...
